ABSTRACT NUMBER – 1012
Preclinical studies have demonstrated that the oncolytic reovirus Pelareorep can enhance the tumor microenvironment by promoting the infiltration of tumor-infiltrating lymphocytes and increasing the expression of PD-1/PD-L1, thus laying the foundation for advancements in immune checkpoint blockade. The results presented at the ASCO 2023 conference, as of the data cutoff date in May 2023, included the enrollment of approximately 48 patients between June 2020 and June 2022.
Three enrolled patients withdrew their consent before initiating therapy, and two discontinued treatment after the first week. Therefore, these patients were considered non-responders and excluded from the progression-free survival (PFS) analysis. Regrettably, 9 patients (33%) discontinued pelareorep treatment, while 6 patients (35%) discontinued avelumab due to toxicity reasons.
